Another HOP peptide (anti-TPR), which inhibits the HOP-Hsp90 interaction, has been described to induce cell death in several cancer cell lines [48] and produce a cytotoxic effect in glioblastomas [49], highlighting HOP as a potential target for GBM therapy. Here, STIP1 is linked to cancer.